Advisory Research Inc. continued to hold its stake in Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 106,195 shares of the company’s stock at the close of the 2nd quarter. Advisory Research Inc.’s holdings in Johnson & Johnson were worth $13,227,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of JNJ. State Street Corp boosted its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares during the last quarter. BlackRock Inc. boosted its stake in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after acquiring an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after acquiring an additional 2,581,562 shares during the last quarter. 65.89% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson (NYSE JNJ) traded up $0.55 during midday trading on Tuesday, reaching $141.14. 4,358,600 shares of the company’s stock traded hands, compared to its average volume of 5,861,946. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market cap of $377,697.84, a PE ratio of 19.69, a PEG ratio of 2.86 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the prior year, the company posted $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. analysts forecast that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.38%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

JNJ has been the topic of a number of recent research reports. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday, October 18th. Citigroup initiated coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price target on the stock. Goldman Sachs Group cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and upped their price target for the company from $125.00 to $130.00 in a research note on Wednesday, September 20th. Finally, Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $145.00 to $157.00 in a research note on Wednesday, October 11th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $144.59.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/12/12/johnson-johnson-jnj-holdings-held-by-advisory-research-inc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.